MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in Macrophages and Endothelial Systems

Executive Summary: MCC950 sodium (CAS 256373-96-3) is a potent, selective small-molecule inhibitor of the NLRP3 inflammasome, showing an IC₅₀ of 7.5 nM in murine bone marrow-derived macrophages (BMDMs) and comparable potency in human monocyte-derived macrophages (HMDMs) [APExBIO]. It blocks both canonical and noncanonical NLRP3 activation without affecting AIM2, NLRC4, or NLRP1 inflammasomes [Yuan et al. 2022]. MCC950 sodium demonstrates high aqueous solubility (≥124 mg/mL in water) and stability when stored at -20°C. In cell and animal models, it specifically inhibits interleukin-1β (IL-1β) release without suppressing TNF-α, confirming selectivity for NLRP3-driven responses. These properties position MCC950 sodium (B7946) as a crucial reagent for mechanistic and translational studies of NLRP3-associated inflammation.

Biological Rationale

The NLRP3 inflammasome is a cytosolic multiprotein complex that senses cellular stress, damage, and pathogens. Upon activation, NLRP3 recruits ASC and pro-caspase-1, leading to caspase-1 activation, IL-1β and IL-18 maturation, and pyroptotic cell death [Yuan et al. 2022]. NLRP3-driven inflammation underpins diverse pathologies, including atherosclerosis, autoimmune diseases, and metabolic syndromes. Excessive or dysregulated NLRP3 activation in endothelial and immune cells contributes to chronic inflammation, cell death, and tissue damage. Selective inhibition of NLRP3, without perturbing other inflammasomes (AIM2, NLRC4, NLRP1), is essential for dissecting its unique role in disease mechanisms [Transforming NLRP3 research]. MCC950 sodium provides this selectivity, enabling causal studies and therapeutic exploration.

Mechanism of Action of MCC950 sodium

MCC950 sodium, also known as CRID3 sodium salt, inhibits NLRP3 activation by directly targeting the ATPase activity of the NLRP3 NACHT domain. This blocks both canonical (e.g., LPS + ATP) and noncanonical (e.g., intracellular LPS-induced) pathways of NLRP3 inflammasome assembly [APExBIO]. As a result, MCC950 sodium prevents caspase-1 activation, pro-IL-1β and pro-IL-18 processing, and pyroptosis. Notably, MCC950 sodium does not inhibit inflammasomes driven by AIM2, NLRC4, or NLRP1, supporting its use in studies requiring high signaling specificity [Advancing Translational Research]. MCC950 sodium is highly soluble (≥124 mg/mL in water), facilitating preparation of concentrated stock solutions and flexible dosing across in vitro and in vivo models.

Evidence & Benchmarks

• MCC950 sodium inhibits NLRP3 activation in murine BMDMs with an IC₅₀ of 7.5 nM (APExBIO, product page).
• Comparable inhibitory potency is observed in human monocyte-derived macrophages (HMDMs) (APExBIO, product page).
• MCC950 sodium does not block AIM2, NLRC4, or NLRP1 inflammasome activation (Yuan et al. 2022, DOI).
• In HUVECs, MCC950 sodium (10 μM, 2 h) suppresses pyroptosis induced by H₂O₂ and decreases IL-1β release (Yuan et al. 2022, DOI).
• Intraperitoneal MCC950 sodium reduces serum IL-1β and IL-6 after LPS challenge in animal models (APExBIO, product page).
• Does not impair TNF-α secretion in primary human PBMCs, confirming selectivity for IL-1β inhibition (APExBIO, product page).
• Attenuates disease severity in experimental autoimmune encephalomyelitis (EAE) models (APExBIO, product page).

Applications, Limits & Misconceptions

MCC950 sodium is a standard tool compound for dissecting NLRP3-mediated signaling in inflammation, cell death (pyroptosis), and autoimmune disease models. It is widely used in studies of endothelial cell dysfunction and atherosclerosis, facilitating mechanistic evaluation of NLRP3 involvement in disease progression. MCC950 sodium enables targeted therapeutic exploration in preclinical animal models, including EAE and LPS-induced systemic inflammation.

This article builds on MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in..., clarifying the molecular specificity of MCC950 sodium and providing updated quantitative benchmarks from recent endothelial cell studies. For a broader context on advanced experimental strategies, see MCC950 Sodium: Illuminating NLRP3 Inflammasome Pathways, which focuses on translational implications.

Common Pitfalls or Misconceptions

• MCC950 sodium is not a pan-inflammasome inhibitor: It is highly selective for NLRP3 and does not inhibit AIM2, NLRC4, or NLRP1.
• Concentration and exposure time matter: Effective inhibition requires nanomolar to low micromolar dosing and pre-incubation (typically ≥1 h) in cellular assays.
• Not suitable for chronic long-term solution storage: Stock solutions should be freshly prepared and kept at -20°C to maintain potency.
• Does not block TNF-α or general cytokine production: MCC950 selectively reduces IL-1β and IL-18 maturation via NLRP3/caspase-1 axis.
• Species differences: While potent in mouse and human macrophages, confirm activity in other species/cell types before assuming equivalence.

Workflow Integration & Parameters

MCC950 sodium (B7946) is supplied as a lyophilized powder and exhibits excellent solubility: ≥124 mg/mL in water, ≥21.45 mg/mL in DMSO, and ≥43 mg/mL in ethanol. For cell-based assays, prepare fresh stock solutions in DMSO or water. Typical working concentrations range from 10 nM to 10 μM. For macrophage or endothelial cell assays, pre-incubate cells with MCC950 sodium for 1–2 h prior to inflammasome activation. In animal models (e.g., EAE, LPS challenge), intraperitoneal dosing regimens are commonly used. Store the powder at -20°C and avoid repeated freeze-thaw cycles.

For troubleshooting and workflow optimization, see MCC950 Sodium: Selective NLRP3 Inflammasome Inhibition in..., which details best practices in both macrophage and endothelial systems.

Conclusion & Outlook

MCC950 sodium is a validated, highly selective NLRP3 inflammasome inhibitor with robust quantitative benchmarks in murine and human models. By enabling precise dissection of NLRP3-driven pyroptosis and cytokine maturation, it has become a foundational tool in inflammatory and autoimmune disease research. Future studies will further define its translational potential, especially in complex disease models where NLRP3 plays a causative role. For product details and ordering, refer to the MCC950 sodium product page.